Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes

Cancer Immunology Immunotherapy

Volumn 42, Issue 4, 1996, Pages 237-245

  Arca, Marjorie J ^a   Krauss, John C ^b   Strome, Scott E ^c   Cameron, Mark J ^a   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

adoptive immunotherapy; cytokines; gene therapy; melanoma; vaccine

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; IMMUNOGENICITY; MELANOMA B16; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CYTOKINES; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PHENOTYPE; TRANSDUCTION, GENETIC; VACCINES;

EID: 0030001007     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050276     Document Type: Article

References (29)

1. Arca MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE (1996) Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete GM-CSF. Cancer Gene Therapy 3:39
2. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell mediated tumor immunity. J Exp Med 179:523
3. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocytc-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539
4. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397
5. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990) Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820
6. Geiger JD, Wagner PD, Shu S, Chang AE (1992) A novel role of autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg Oncol 1:199
7. Geiger JD, Wagner PD, Cameron MJ, Shu S, Chang AE (1993) Generation of T cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother 13:153
8. Geraghty PJ, Chang AE (1995) Basic principles associated with gene therapy of cancer. Surg Oncol 4:125
9. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young HA, Wiltrout RH, Ochoa AC (1995) Gradual loss of T helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 87:1478
10. Hart IR (1979) The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 97:587
11. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD (1992) Inhibition of tumor-specific cytotoxic T lymphocyte responses by transforming growth factor β1. Cancer Res 52:1386
12. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. J Immunol 155:2240
13. McDougall CJ, Ngoi SS, Goldman IS, Godwin T, Felix J, DeCosse JJ, Rigas B (1990) Reduced expression of HLA Class I and II antigens in colon cancer. Cancer Res 50:8023
14. Miller AR, McBride WH, Hunt K, Economou JS (1994) Cytokine-mediated gene therapy for cancer. Ann Surg Oncol 1:436
15. Mizoguchi H, O'shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795
16. Nathanson SD, Haas GP, Mead MJ, Lee M (1986) Spontaneous regional lymph node metastases of three variants of the B16 melanoma: Relationship to primary tumor size and pulmonary metastases. J Surg Oncol 33:41
17. Nestle FO, Buchner S, Nickoloff B, Burg G (1995) Induction of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) on peritumoral antigen-presenting cells in basal cell carcinomas treated with IFN-alpha. J Invest Dermatol 105:492
18. Nestle FO, Burg G, Fäh J, Nickoloff B (1996) In vivo and in vitro characterization of human tumor associated dendritic cells: deficiency in T cell co-stimulatory molecules and impaired antigen-presenting function
19. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L (1993) Antimetastatic vaccination of tumor-hearing mice with two types of IFN-γ gene-inserted tumor cells. J Immunol 150:1458
20. + T cells against the wild type tumor: correlation with antigen presentation capability. J Exp Med 175:1423
21. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109
22. Salvadori S, Gansbacher B, Pizzimenti AM, Zier KS (1994) Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2 secreting tumors. J Immunol 153:5176
23. Strome SE, Krauss JC, Cameron MJ, Forslund K, Shu S, Chang AE (1993) Immunobiologic effects of cytokine gene transfer of the B16-BL6 melanoma. Arch Otolaryngol Head Neck Surg 119:1289
24. Strome SE, Chang AE, Shu S, Krauss JC (1996) Secretion of both IL-2 and IL-4 by tumor cells results in rejection and immunity. J Immunother 19: 21
25. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT (1995) Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 154:6466
26. Tanaka K, Gorelik E, Watanabe M, Hozumi N, Jay G (1988) Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol Cell Biol 8:1857
27. Weber JS, Rosenberg SA (1990) Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes. J Natl Cancer Inst 82:755
28. Weber JS, Jay G, Tanaka K, Rosenberg SA (1987) Immunotherapy of a murine tumor with interleukin-2. Increased sensitivity after MHC class I gene transfection. J Exp Med 166:1716
29. Zea AH, Curti BD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, Creekmore SP, O'shea JJ, Powers GC, Urba WJ, Ochoa AC (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1:1327